| Role |
Name |
Disclosure |
Details |
| Author | Anna M Barrett, MD, Associate Professor of Physical Medicine and Rehabilitation and Neurology and Neurosciences, University of Medicine and Dentistry of New Jersey, New Jersey Medical School; Director, Stroke Rehabilitation Research Program, Kessler Medical Rehabilitation Research and Education Center | Nothing to disclose | Details | | Medical Editor | Daniel H Jacobs, MD, Associate Professor of Neurology, University of Central Florida College of Medicine | Teva Pharmaceutical Biogen Idex Serono EMD Pfizer Berlex | Details | | Pharmacy Editor | Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine | Nothing to disclose | Details | | Managing Editor | Richard J Caselli, MD, Professor, Department of Neurology, Mayo Medical School, Rochester, MN; Chair, Department of Neurology, Mayo Clinic of Scottsdale | Nothing to disclose | Details | | CME Editor | Matthew J Baker, MD, Consulting Staff, Collier Neurologic Specialists, Naples Community Hospital | Nothing to disclose | Details | | Chief Editor | Howard A Crystal, MD, Professor, Departments of Neurology and Pathology, State University of New York Downstate; Consulting Staff, Department of Neurology, University Hospital and Kings County Hospital Center | Pfizer Myriad | Details |
Contributor Disclosure
Contributor:
|
Contributor Disclosure: |
| Richard J Caselli, Managing Editor |
The contributor discloses no conflict of interest. |
Contributor Disclosure
Contributor:
|
Contributor Disclosure: |
| Matthew J Baker, CME Editor |
The contributor discloses no conflict of interest. |
|